Investing, Stocks, Stocks to Buy

This Healthcare Stock Is Down 40%, But the Growth Story Isn’t Dead

TransMedics stock has been crushed, but its transplant platform may still be building a moat investors shouldn’t ignore.

Written by: Rick Orford

Edited by: Mike Reyes

Last Updated June 3, 2026

Disclaimer

This content is not intended to provide financial advice; rather, it’s for information and entertainment purposes only.

Always consult a licensed advisor for investment decisions.

Some of the links in this article may be affiliate links. If you click on a link, the affiliate may provide compensation to this site at no cost to you, regardless if you decide to purchase something. You can read our affiliate disclosure in our privacy policy.

Finally, this article has been written, reviewed, and fact-checked. Portions of this article have been written using assistive AI tools to help with tasks like research, spell-checking, grammar, and translation. Please have a look at our editorial guidelines for more information about how we create content.

TransMedics (NASDAQ:TMDX) faces a serious margin test after a rough stock decline, but revenue growth remains strong. The central question is whether heavy infrastructure spending is a temporary drag, or a warning sign that the business is becoming harder to scale profitably.

Stock prices used were the market prices of May 25, 2026. The video was published on June 1, 2026. On the date of publication, Rick Orford did not have (either directly or indirectly) positions in any of the securities mentioned in this video.

Share this post:

X (Twitter) Facebook Pinterest LinkedIn Email

Previous

The $190 Billion Question Hanging Over Alphabet Stock

Next

Zeta Stock Is Up 42%. The Next Move Depends on AI